THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS

被引：0
|
作者：
Forte, L. [1 ]
Malmberg, C. [1 ]
Mann, K. [1 ]
Jupe, K. [1 ]
Chow, G. [1 ]
Lech, R. A. [1 ]
Kulik, R. [1 ]
机构：
[1] Patient Access Solut, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRO78
引用
收藏
页码：S855 / S855
页数：1
相关论文
共 50 条
  • [1] Impact of orphan drugs on Latvian budget
    Konstantins Logviss
    Dainis Krievins
    Santa Purvina
    Orphanet Journal of Rare Diseases, 11
  • [2] Impact of orphan drugs on Latvian budget
    Logviss, Konstantins
    Krievins, Dainis
    Purvina, Santa
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [3] THE BUDGET IMPACT OF ORPHAN DRUGS IN THE US AND CANADA: A 2007-2013 MIDAS SALES DATA ANALYSIS
    Divino, V
    DeKoven, M.
    Kim, T.
    Kleinrock, M.
    Wade, R. L.
    Kaura, S.
    VALUE IN HEALTH, 2015, 18 (07) : A666 - A666
  • [4] TREND ANALYSIS OF LISTING AND BUDGET IMPACT FOR ORPHAN DRUGS IN KOREA
    Kim, Y.
    Oh, R.
    VALUE IN HEALTH, 2017, 20 (09) : A567 - A567
  • [5] Budget-impact of drugs for orphan diseases (orphan drugs) in the Israeli health basket: a longitudinal analysis
    Morginstin, Tal
    Hammerman, Ariel
    Triki, Noa
    Weinreb, Baruch
    ISRAEL JOURNAL OF HEALTH POLICY RESEARCH, 2019, 8 (01):
  • [6] BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
    Saggia, M. G.
    Santos, E. A.
    VALUE IN HEALTH, 2009, 12 (07) : A436 - A437
  • [7] The Budget Impact of Orphan Drugs in the US: A 20072013 MIDAS Sales Data Analysis
    Divino, Victoria
    Dekoven, Mitch
    Wang, Weiying
    Kleinrock, Michael
    Harvey, R. Donald
    Wade, Rolin L.
    Kaura, Satyin
    BLOOD, 2014, 124 (21)
  • [8] REVIEW OF METHODOLOGICAL QUALITY OF BUDGET IMPACT ANALYSES FOR ORPHAN DRUGS
    Abdallah, K.
    Kiani, P.
    Huys, I
    Claes, K.
    Simoens, S.
    VALUE IN HEALTH, 2019, 22 : S771 - S771
  • [9] Access to orphan drugs in Europe: current and future issues
    Michel, Morgane
    Toumi, Mondher
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (01) : 23 - 29
  • [10] Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe
    Schlander, Michael
    Adarkwah, Charles Christian
    Gandjour, Afschin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (01) : 171 - 179
12345